Five Steps to Medical Device Commercialization

Share this:

Bringing medical devices to market in the United States can be a complex process, requiring an understanding of FDA requirements and processes. There are a number of factors to consider, including a device’s classification, premarket preparation and submission to the FDA. Being familiar with the process, as well as ever-changing guidance from the FDA, can help manufacturers get devices to market more easily and effectively.

The Process

The process of bringing a product to market in the United States can be summed up with five steps, all of which require following FDA guidance and regulation.

Classifying your device. The first step in the process is to determine the type of device you’re bringing to market. There are three different class types, based on three considerations: Risk to the patient/user, intended use and indications for use. Indications can give further specificity to a device. For example, a scalpel has an intended use to make an incision, but a scalpel indicated for ocular uses has a higher risk level and may be classified differently.

Class I devices pose the lowest risk and, as such, are subject to general controls. Class II devices illustrate moderate risk and require special controls in addition to general ones. High-risk, or Class III, devices require general controls as well as premarket approval (PMA) (Class I and some Class II devices are exempt from PMA). Given the different levels of control, and the potential for premarket approval, the classification of a device plays a key role and will also determine how to continue on the path to bringing a device to market, as it will inform the next steps in the process.

Identifying the correct premarket submission. The appropriate premarket submission will depend on the device’s classification. The most common types of submission include the 510(k) premarket notification, PMA application, De Novo Evaluation of Automatic Class III Designation and the humanitarian device exemption (HDE). In order to determine which submission will apply to a given device, consider the product’s class, indication, and existing devices and technology.

A 510(k) notification is used for a new device that is “substantially equivalent” to a predicate device as far as its intended use, technological characteristics and performance testing. This type of submission usually applies to some Class I and most Class II devices, unless they are considered exempt under the limitations of exemption stated in 21 CFR xxx 9, where xxx refers to 21 CFR 862-892.

For a new device without a valid predicate to be classified as a Class I or Class II device, the FDA developed the De Novo Evaluation designation. Previously, these devices were classified as Class III given the lack of a predicate device after their 510(k) review. However, under this designation, a device can still be classified as Class I or II, which could result in a more efficient review process, as the device will not be subject to the PMA process.

The PMA is the most stringent premarket submission, requiring information on how the device was designed, how it is manufactured and valid scientific evidence demonstrating reasonable assurance of safety and effectiveness for the device’s intended use through preclinical and clinical studies. Because of this requirement for clinical trials, a PMA is significantly more expensive than a 510(k) or De Novo Evaluation.

Most Class III devices require a premarket approval. Because of the stringent standards at play with a PMA, it is important to note that for these devices, the FDA must receive an application and provide approval before the device can be marketed.

The HDE applies specifically to devices that are intended to benefit patients in the treatment of rare diseases or conditions, meaning one that is affected or manifested in fewer than 4,000 individuals in the United States each year. To qualify for an HDE, the product must obtain a Humanitarian Use Device (HUD) designation from the FDA’s Office of Orphan Products Development (OOPD). The HDE submission is similar in form and content to a PMA, but is exempt from the effectiveness requirements. Also, it must be proven that there are not comparable devices available to treat or diagnose the disease or condition and the device could not otherwise be brought to market.

Preparing the premarket submission. To adequately prepare your premarket submission, it’s important to know what information must be included. Design controls, nonclinical testing, clinical evidence and labeling are all important items to consider, based on your device’s classification.

Keep in mind that higher risk devices require much more detailed information, including clinical and usability data, than lower risk devices, which may be cleared with non-clinical performance data and bench test information. Based on your device classification and premarket submission, it is important to plan accordingly.

Submitting to the FDA. After the information is compiled, it must be sent to the FDA for review, which can take anywhere from 90 days for a traditional 510(k) to more than 180 days for a PMA. When doing the initial submission, you will need to include an electronic copy of your application and, in the case of a 510(k) or PMA, the associated fee.

After submission, the FDA will conduct an administrative review to determine if the submission is sufficiently complete. FDA staff will communicate with applicants throughout the review process to make the process more efficient. Requests for additional information are possible, with a response time of 30–180 days accompanying said requests. Failure to respond within 180 days will result in a submission being considered withdrawn and the need to start the process over.

When conducting site inspections, priority will be given to manufacturers with pending PMAs, Class III manufacturers that have never been inspected, compliance follow up, for-cause inspections and manufacturers of high-risk devices.

Establishing registration and device listing. The final step is to register the device’s establishment and list with the FDA, after premarket approval is granted (when needed). Keep in mind that registration of a device establishment, assignment of a registration number or listing of a medical device does not denote clearance or approval by the FDA.

Current Guidance from the FDA

It is always important to stay informed of new guidance documents issued by the FDA, as they relate to medical devices. In 2016 the FDA has issued a number of new final guidance documents. Relevant to market entry are the following documents:

Guidance for Industry and Food and Drug Administration Staff – Factors to Consider When Making Benefit-Risk Determinations in Medical Device Premarket Approval and De Novo Classifications

Use of International Standard ISO 10993-1, “Biological evaluation of medical devices – Part 1: Evaluation and testing within a risk management process” – Guidance for Industry and Food and Drug Administration Staff

In addition, the FDA has also issued draft guidance documents and seeks feedback from industry on their content. The recent draft guidance documents of interest to manufacturers of Internet-based devices include:

Deciding When to Submit a 510(k) for a Software Change to an Existing Device – Draft Guidance for Industry and Food and Drug Administration Staff

These are but a small subset of the guidance documents issued by the FDA. Manufacturers are recommended to review the list of current and past guidance documents on the FDA website to find any that may be relevant to the device that they intend to market. Use of and compliance with FDA guidance may provide a shorter review cycle and a higher probability of success the first time through.

Final Tips

The medical device market in the United States can offer manufacturers great opportunity, provided they can successfully navigate the many requirements and multiple-step process. Getting a device through the FDA procedure and on the U.S. market can take time. Familiarizing yourself with the process and various requirements is a good idea. You may also want to enlist the help of experts in the area who know the ins and outs of the procedure. Do the due diligence to collect information for the device application and stay in communication with the FDA throughout the process. These steps can help with the submission process and bring the product to market more efficiently.

About The Author

Michael Lynch is a seasoned medical device product development professional with more than 30 years’ experience spanning a range of products, including high-volume disposable drug delivery systems, orthopedic implants and electro-mechanical capital equipment. He has managed the product development process from concept through full-scale manufacture, is co-inventor on five U.S. patents and is recognized within the industry for his technical competence and ability to identify issues during design reviews.

Comments

Yes, Yes — but an important point that many smaller firms miss is that the process has to start as soon as the idea doesn’t get laughed at.

My definition of Commercialization differs in it includes everything needed to get from a great idea to a shipping product. Certainly the regulatory has to take center stage in the plans, and Michael’s firm does a great job of the regulatory.

The FDA and the rest of the regulatory bodies want to look at the great records your amazing quality system has been keeping up with every step of the way. You CANNOT make up for lost ground when you decide you feel like shipping the thing (or even marketing it.)

Upcoming Events & Webinars

The regulations are there for anyone to read, but even the largest, best-prepared companies have large teams struggling with implementation. There is no easy answer, but we are all in this together, and by pooling thoughts and solutions can expedite the process for everyone. This two-day workshop convenes experts from major companies, notified bodies, and consulting firms to share strategies, procedures, experiences, and challenges.

CAPA is the most critical and challenging quality system requirement in terms of complex thinking and organizational processes. Not a CAPA 101 course, this workshop brings together leading industry CAPA process owners to discuss approaches to the most difficult problems in CAPA and root cause analysis. Registration will open soon.

Deficiencies in process validation and other aspects of production and process control earn more FDA enforcement actions than any other quality function except CAPA. This two-day workshop addresses key issues in process validation, including risk-based determination of processes to be validated, FDA and 13485:2016 requirements, key process validation elements and best practices, statistical and other tools, maintaining the validated state, and documentation.

The new European medical device regulation imposes a broad array of stringent new requirements on medical device manufacturers. This program takes a high-level approach to the business strategy and organizational challenges of evaluating a company’s portfolio of legacy and pipeline products to determine the impact of the new regulation, perform a gap analysis, calculate the profit and cost of remediation, establish a timed and stratified approach, and to modify or create those internal structures needed to bring current products into compliance and to efficiently maintain compliance in the future. Registration will open soon.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

You can adjust all of your cookie settings by navigating the tabs on the left hand side.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

We use tracking pixels that set your arrival time at our website, this is used as part of our anti-spam and security measures. Disabling this tracking pixel would disable some of our security measures, and is therefore considered necessary for the safe operation of the website. This tracking pixel is cleared from your system when you delete files in your history.

We also use cookies to store your preferences regarding the setting of 3rd Party Cookies.

disable

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

Cookie Policy

A browser cookie is a small piece of data that is stored on your device to help websites and mobile apps remember things about you. Other technologies, including Web storage and identifiers associated with your device, may be used for similar purposes. In this policy, we say “cookies” to discuss all of these technologies.

Our Privacy Policy explains how we collect and use information from and about you when you use This website and certain other Innovative Publishing Co LLC services. This policy explains more about how we use cookies and your related choices.

How We Use Cookies

Data generated from cookies and other behavioral tracking technology is not made available to any outside parties, and is only used in the aggregate to make editorial decisions for the websites. Most browsers are initially set up to accept cookies, but you can reset your browser to refuse all cookies or to indicate when a cookie is being sent by visiting this Cookies Policy page. If your cookies are disabled in the browser, neither the tracking cookie nor the preference cookie is set, and you are in effect opted-out.

In other cases, our advertisers request to use third-party tracking to verify our ad delivery, or to remarket their products and/or services to you on other websites. You may opt-out of these tracking pixels by adjusting the Do Not Track settings in your browser, or by visiting the Network Advertising Initiative Opt Out page.

You have control over whether, how, and when cookies and other tracking technologies are installed on your devices. Although each browser is different, most browsers enable their users to access and edit their cookie preferences in their browser settings. The rejection or disabling of some cookies may impact certain features of the site or to cause some of the website’s services not to function properly.

Individuals may opt-out of 3rd Party Cookies used on IPC websites by adjusting your cookie preferences through this Cookie Preferences tool, or by setting web browser settings to refuse cookies and similar tracking mechanisms. Please note that web browsers operate using different identifiers. As such, you must adjust your settings in each web browser and for each computer or device on which you would like to opt-out on. Further, if you simply delete your cookies, you will need to remove cookies from your device after every visit to the websites. You may download a browser plugin that will help you maintain your opt-out choices by visiting www.aboutads.info/pmc. You may block cookies entirely by disabling cookie use in your browser or by setting your browser to ask for your permission before setting a cookie. Blocking cookies entirely may cause some websites to work incorrectly or less effectively.

The use of online tracking mechanisms by third parties is subject to those third parties’ own privacy policies, and not this Policy. If you prefer to prevent third parties from setting and accessing cookies on your computer, you may set your browser to block all cookies. Additionally, you may remove yourself from the targeted advertising of companies within the Network Advertising Initiative by opting out here, or of companies participating in the Digital Advertising Alliance program by opting out here.